about
Fulminant Wilson's Disease Managed with Plasmapheresis as a Bridge to Liver TransplantFatal cytomegalovirus disease after combination therapy with corticosteroids and rituximab for granulomatosis with polyangiitis.Diffuse unresolving pulmonary nodules in a patient with a history of cervical carcinoma.Sudden cardiac arrest in a healthy young athlete.Maintaining sharp focus on a grainy film: miliary pattern in an elderly woman with acute respiratory failure.Radiation-induced breast cancer: the question of early breast cancer screening in Hodgkin's lymphoma survivors.Current understanding and approach to well differentiated lung neuroendocrine tumors: an update on classification and management.A tick-borne illness unmasking asymptomatic Brugada syndrome.Disseminated tuberculosis with tuberculous meningitis in an immunocompetent host.The perils of country life: human monocytic ehrlichiosis.A cause to consider for chronic unresolving diarrhea.Comprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapy.Cytomegalovirus reactivation is associated with a lower rate of early relapse in myeloid malignancies independent of in-vivo T cell depletion strategy.Chronic rupture of the coronary sinus of Valsalva with pseudoaneurysm formation.Exploring the possibilities: airspace disease in the postallogeneic haematopoietic stem cell transplant period.B-cell acute lymphoblastic leukemia with +der(1)t(1;19) (p13;p13.1) arising in the setting of CALR exon 9 mutated essential thrombocythemia.Nivolumab associated bone marrow necrosis.A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma.Myeloid neoplasm with eosinophilia associated with isolated extramedullary FIP1L1/PDGFRA rearrangement.Rituximab Maintenance Therapy After First-Line Induction Chemoimmunotherapy for Follicular Lymphoma.Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections.Necrobiotic xanthogranuloma: a 30-year single-center experience.Contrast-Enhanced Spectral Mammography is Comparable to MRI in the Assessment of Residual Breast Cancer Following Neoadjuvant Systemic TherapyASO Author Reflections: Role of Contrast-Enhanced Spectral Mammography in the Assessment of Residual Breast Cancer After Neoadjuvant Systemic TherapyUnexpected Cardiac MassesAdjuvant Antiangiogenic Agents in Post-nephrectomy Renal Cell Carcinoma: A Systematic Review and Meta-analysisBilateral upper lobe opacificationERBB2 (HER2) Testing in Breast CancerEconomic Impact of Oral Therapies for Chronic Lymphocytic Leukemia-the Burden of NoveltyRituximab maintenance therapy for mantle cell lymphoma: A systematic review and meta-analysisBreast MRI phenotype and background parenchymal enhancement may predict tumor response to neoadjuvant endocrine therapyHemostatic complications associated with ventricular assist devicesGone But HereEliminating MRD - FDA approval of blinatumomab for B-ALL in complete remissionI Don't KnowAnalysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug AdministrationGerm Cell Tumors with Malignant Somatic Transformation: A Mayo Clinic ExperienceChange in 21-gene Recurrence Score result after exposure to neo-adjuvant endocrine therapy in patients with operable breast cancerHanging Up the GlovesNeutropenic diets to prevent cancer infections: updated systematic review and meta-analysis
P50
Q34243046-FAE4DA99-F2BD-4282-B3A5-5BF58FE9B338Q35034085-7259BC1B-D888-411E-959E-253C9A7C5365Q35467684-068EA674-100E-47CF-BDDE-1842BCD73A77Q35808330-BB1063B0-85AA-49C1-A0DC-1C8E9D496339Q35885090-DD176AD7-2953-4352-B914-5B4A9ABD2F47Q36592404-C3889C0A-6A4A-4F11-AA8A-9CBFCE7F8438Q37698605-8C7C3CB3-AF8C-4B9A-803F-6B2AF1D74E5FQ40155455-D00ADEE7-CBBF-42D7-A1E2-ED1B15F229CFQ41219967-5241FB9E-52A5-47C9-9D38-21018BA09DBEQ41286455-8C1B1D35-A9D1-4B73-A614-1A14AAE769E9Q41344751-CC3B9E3E-B4C0-4CC6-8D3C-5B176990AE81Q41571663-A9CA2B58-978D-424D-A8DA-720C9D4A5C88Q41985146-B740C151-2FA0-42FF-A624-E2D3FFD1A3C9Q43052671-433128AE-FC70-4A43-B4AB-CB6E31850E8CQ43184646-788FC36C-737A-4E7A-A4DB-C7AAEC607FE5Q49889692-0C75EFA8-C60E-404C-92C1-6ADEB7340256Q49916816-1AA4AB01-DEB6-460B-AB40-1DCC8A2E39F9Q50102737-0E76E34C-51E1-4CDB-A856-1B88D981A730Q50134978-ADFE14B4-FA4A-4F1B-A57B-28C1DBF8D826Q52621965-34369F34-FD93-4369-98F0-B3FBA49E3E17Q52724626-6712CD5E-93F0-44D5-BF58-473A983DF521Q52724759-38C00BBB-E8C0-4DF6-B5F9-E79B534C509FQ57113071-E992F6F7-22AD-4F25-8291-BA5EA22B8722Q57461205-51FA58A1-9EA5-4AA9-8FF5-D46B1EEF925CQ57641745-2F3FFBA3-CA3C-479D-872C-C669AE67B347Q57825312-B2585AA2-BA14-4A5D-BAAF-3E88E5D6B3AEQ85363307-E64EF3D8-532C-4F9B-8358-67605D304381Q89036823-66BCC7E4-C30B-4F6C-A3E8-7DCB9FA784E2Q89459131-69F42D3B-459D-4C57-8E3D-7D4D9AD8F6AEQ90396176-22DD8779-3BA0-4741-B820-9CAB377B776BQ90680515-08D6FB24-3F98-492D-9E3F-5D3CD7956709Q90784703-EAA1A0D9-8A90-428E-B282-24D1B05F66EDQ91008785-F65C7784-02D3-40AF-8EE9-D99235081F58Q91289754-142BC6E8-AE9A-4809-B019-C7AF6505E5B1Q91513667-F77EB1DC-A3CE-4756-AE1F-EC79F89E1322Q91694148-F8742739-8E41-4578-A40E-147DA6BC7B38Q92023356-24F20BA8-D577-41AA-92FF-66685C2A5E37Q92245785-BC8C5749-CDEB-4F20-9DFB-1824B9510553Q92253527-3472A1B2-EDC8-431D-BE84-C83CE2FE79BAQ92859069-8CA1E021-F6CE-43A8-957F-5EA04D6C60A6
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Talal Hilal
@ast
Talal Hilal
@en
Talal Hilal
@es
Talal Hilal
@sl
type
label
Talal Hilal
@ast
Talal Hilal
@en
Talal Hilal
@es
Talal Hilal
@sl
prefLabel
Talal Hilal
@ast
Talal Hilal
@en
Talal Hilal
@es
Talal Hilal
@sl
P106
P1153
16241227400
P31
P3835
talal-hilal2
P496
0000-0001-8249-4128